171 related articles for article (PubMed ID: 1829886)
1. A cyclopeptidic suicide substrate preferentially inactivates urokinase-type plasminogen activator.
Reboud-Ravaux M; Vilain AC; Boggetto N; Maillard J; Favreau C; Xie J; Mazaleyrat JP; Wakselman M
Biochem Biophys Res Commun; 1991 Jul; 178(1):352-9. PubMed ID: 1829886
[TBL] [Abstract][Full Text] [Related]
2. Amiloride selectively inhibits the urokinase-type plasminogen activator.
Vassalli JD; Belin D
FEBS Lett; 1987 Apr; 214(1):187-91. PubMed ID: 3106085
[TBL] [Abstract][Full Text] [Related]
3. On the target specificity of plasminogen activator inhibitor 1: the role of heparin, vitronectin, and the reactive site.
Keijer J; Linders M; Wegman JJ; Ehrlich HJ; Mertens K; Pannekoek H
Blood; 1991 Sep; 78(5):1254-61. PubMed ID: 1715220
[TBL] [Abstract][Full Text] [Related]
4. Poly-D-lysine dependent inactivation of tissue plasminogen activator by a class PAI-2 inhibitor (minactivin).
Leung KC; Byatt JA; Stephens RW
Thromb Res; 1987 Jun; 46(6):767-77. PubMed ID: 3114909
[TBL] [Abstract][Full Text] [Related]
5. Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme.
Andreasen PA; Nielsen LS; Kristensen P; Grøndahl-Hansen J; Skriver L; Danø K
J Biol Chem; 1986 Jun; 261(17):7644-51. PubMed ID: 3086313
[TBL] [Abstract][Full Text] [Related]
6. Kinetics of inhibition of tissue-type and urokinase-type plasminogen activator by plasminogen-activator inhibitor type 1 and type 2.
Thorsen S; Philips M; Selmer J; Lecander I; Astedt B
Eur J Biochem; 1988 Jul; 175(1):33-9. PubMed ID: 3136015
[TBL] [Abstract][Full Text] [Related]
7. Purification of epidermal plasminogen activator inhibitor.
Hibino T; Izaki S; Izaki M
FEBS Lett; 1986 Nov; 208(2):273-7. PubMed ID: 3096778
[TBL] [Abstract][Full Text] [Related]
8. Inhibition in purified systems and in human plasma of chimaeric plasminogen activators consisting of the NH2-terminal region of tissue-type plasminogen activator and the COOH-terminal region of urokinase-type plasminogen activator.
Lijnen HR; Nelles L; Van Hoef B; De Cock F; Collen D
Thromb Haemost; 1988 Oct; 60(2):247-50. PubMed ID: 3146141
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the dexamethasone-induced inhibitor of plasminogen activator in HTC hepatoma cells.
Coleman PL; Patel PD; Cwikel BJ; Rafferty UM; Sznycer-Laszuk R; Gelehrter TD
J Biol Chem; 1986 Mar; 261(9):4352-7. PubMed ID: 2936742
[TBL] [Abstract][Full Text] [Related]
10. The irreversible inhibition of urokinase, kidney-cell plasminogen activator, plasmin and beta-trypsin by 1-(N-6-amino-n-hexyl)carbamoylimidazole.
Walker B; Elmore DT
Biochem J; 1984 Jul; 221(1):277-80. PubMed ID: 6235806
[TBL] [Abstract][Full Text] [Related]
11. Kinetic analysis of covalent hybrid plasminogen activators: effect of CNBr-degraded fibrinogen on kinetic parameters of Glu1-plasminogen activation.
Lee PP; Wohl RC; Boreisha IG; Robbins KC
Biochemistry; 1988 Sep; 27(19):7506-13. PubMed ID: 2974723
[TBL] [Abstract][Full Text] [Related]
12. Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained.
Pannell R; Black J; Gurewich V
J Clin Invest; 1988 Mar; 81(3):853-9. PubMed ID: 2963831
[TBL] [Abstract][Full Text] [Related]
13. The plasma inhibitors of plasminogen activator, studied by a zymographic technique.
Booth NA; Anderson JA; Bennett B
Thromb Res; 1985 May; 38(3):261-7. PubMed ID: 3161209
[TBL] [Abstract][Full Text] [Related]
14. Production of proteases type plasminogen activator and their inhibitor in cornea.
Mirshahi M; Mirshahi S; Soria C; Soria J; Thomaidis A; Pouliquen Y; Faure JP
Biochem Biophys Res Commun; 1989 May; 160(3):1021-5. PubMed ID: 2499321
[TBL] [Abstract][Full Text] [Related]
15. Prourokinase activation on the surface of human rhabdomyosarcoma cells: localization and inactivation of newly formed urokinase-type plasminogen activator by recombinant class 2 plasminogen activator inhibitor.
Pöllänen J; Vaheri A; Tapiovaara H; Riley E; Bertram K; Woodrow G; Stephens RW
Proc Natl Acad Sci U S A; 1990 Mar; 87(6):2230-4. PubMed ID: 2138329
[TBL] [Abstract][Full Text] [Related]
16. Hormonal regulation of extracellular plasminogen activators and Mr approximately 54,000 plasminogen activator inhibitor in human neoplastic cell lines, studied with monoclonal antibodies.
Andreasen PA; Christensen TH; Huang JY; Nielsen LS; Wilson EL; Danø K
Mol Cell Endocrinol; 1986 May; 45(2-3):137-47. PubMed ID: 3011558
[TBL] [Abstract][Full Text] [Related]
17. Substrate specificity of tissue-type and urokinase-type plasminogen activators.
Rijken DC; Groeneveld E
Biochem Biophys Res Commun; 1991 Jan; 174(2):432-8. PubMed ID: 1899564
[TBL] [Abstract][Full Text] [Related]
18. Microplate immunocapture assay for plasminogen activators and their specific inhibitors.
Stephens R; Leung KC; Pöllänen J; Salonen EM; Vaheri A
J Immunol Methods; 1987 Dec; 105(2):245-51. PubMed ID: 3121752
[TBL] [Abstract][Full Text] [Related]
19. Susceptibility of plasminogen activators to suicide inactivation.
Mor A; Reboud-Ravaux M; Mazaleyrat JP; Wakselman M
Thromb Res Suppl; 1988; 8():35-44. PubMed ID: 3144767
[TBL] [Abstract][Full Text] [Related]
20. Reaction of thrombin and proteinases of the fibrinolytic system with a mechanism-based inhibitor, 3,4-dihydro-3-benzyl-6-chloromethylcoumarin.
Mor A; Maillard J; Favreau C; Reboud-Ravaux M
Biochim Biophys Acta; 1990 Mar; 1038(1):119-24. PubMed ID: 2138500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
